INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK

Core Viewpoint - A class action lawsuit has been filed against Merck & Co., Inc. concerning allegations of securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that Merck and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Merck securities during the Class Period have until April 14, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Financial Impact - On July 30, 2024, Merck reported a significant reduction in demand for its HPV vaccination Gardasil in China, leading to higher inventory levels and potential shipment shortfalls [4]. - Following this announcement, Merck's stock price dropped by $12.53 per share, or 9.81$115.25 per share [5]. - On February 4, 2025, Merck announced it would not meet the previously forecasted $11 billion sales target for Gardasil by 2030, leading to another stock price decline of$9.05 per share, or 9.07%, closing at $90.74 per share [5].